Letter to the Editor
In a recent article, Mancuso et al. reported about a 19 years-old girl with MELAS syndrome due to the cytb mutation m.15092G>A [1] . We have the following comments and concerns. Mutations in the mitochondrial cytb gene may not only present as MELAS syndrome but with a large phenotypic variability (table  1) . Either a single organ may be affected or several organs are involved (table 1) . In recent studies it has been shown that L-arginine is effective to reduce duration and intensity of SLLs [2, 3] . Did the patient receive L-arginine or other non-specific drugs to recover from recurrent, multifocal SLLs? Why was phenytoin applied as an antiepileptic drug? It is well-known that phenytoin reduces state-3-respiration, the mitochondrial membrane potential, and ATP-production, increases state-4-respiration, impairs calcium uptake and release, and inhibits calcium-induced swelling, mitochondrial Na/K-ATPase, and the Mg-ATPase [4] . There is definitively cardiac involvement in MELAS [5] . Thus, one echocardiography is not enough to rule out cardiac disease. 
Table1. Phenotypic manifestations of mitochondrial cytb mutations

